Status:
COMPLETED
Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
Lead Sponsor:
UCB BIOSCIENCES, Inc.
Conditions:
Epilepsy
Eligibility:
All Genders
12-55 years
Phase:
PHASE2
Brief Summary
To study how the body absorbs, distributes, metabolises and eliminates Keppra XR in both children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.
Eligibility Criteria
Inclusion
- Subjects with a diagnosis of epilepsy on up to three concomitant anti-epileptic drugs
- Subjects on levetiracetam immediate release (IR) can be enrolled if on a stable dose for 7 days
Exclusion
- Subjects with a history of status epilepticus within 3 months of Visit 1
- Subject has difficult venous accessibility
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00961441
Start Date
September 1 2009
End Date
March 1 2010
Last Update
August 6 2015
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Mobile, Alabama, United States
2
Phoenix, Arizona, United States
3
Little Rock, Arkansas, United States
4
Fairfield, Connecticut, United States